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ABSTRACT
Objectives: (A) To measure the extent to which
different candidate outcome measures identified high-
risk prescribing that is potentially changeable by the
data-driven quality improvement in primary care (DQIP)
intervention.(B) To explore the value of reviewing
identified high-risk prescribing to clinicians.(C) To
optimise the components of the DQIP intervention.
Design: Mixed method study.
Setting: General practices in two Scottish Health
boards.
Participants: 4 purposively sampled general practices
of varying size and socioeconomic deprivation.
Outcome measures: Prescribing measures
targeting (1) high-risk use of the non-steroidal anti-
inflammatory drugs (NSAIDs) and antiplatelets; (2)
‘Asthma control’ and (3) ‘Antithrombotics in atrial
fibrillation (AF)’.
Intervention: The prescribing measures were used to
identify patients for review by general practices. The
ability of the measures to identify potentially
changeable high-risk prescribing was measured as the
proportion of patients reviewed where practices
identified a need for action. Field notes were recorded
from meetings between researchers and staff and key
staff participated in semistructured interviews exploring
their experience of the piloted intervention processes.
Results: Practices identified a need for action in 68%,
25% and 18% of patients reviewed for prescribing
measures (1), (2) and (3), respectively. General
practitioners valued being prompted to review patients,
and perceived that (1) ‘NSAID and antiplatelet’ and (2)
‘antithrombotics in AF’ were the most important to act
on. Barriers to initial and ongoing engagement and to
sustaining improvements in prescribing were identified.
Conclusions: ‘NSAIDs and antiplatelets’ measures
were selected as the most suitable outcome measures
for the DQIP trial, based on evidence of this
prescribing being more easily changeable. In response
to the barriers identified, the intervention was designed
to include a financial incentive, additional ongoing
feedback on progress and reprompting review of
patients, whose high-risk prescribing was restarted
after a decision to stop.
Trial registration number: Clinicaltrials.gov
NCT01425502.
BACKGROUND
The safety of medication use in primary care
is a major concern for healthcare systems
internationally.1–4 An estimated 3–4% of
unplanned hospital admissions are due to
preventable adverse drug events and approxi-
mately one-third of these have been attribu-
ted to prescribing of drugs to people with
risk factors for adverse drug effects and
underprescribing of prophylactic treatments
(high-risk prescribing).4
In the UK, medications may be initiated in
primary and secondary care, but general
practitioners (GPs) prescribe almost all drugs
in the community and have responsibility for
reviewing all medications. Previous research
has shown that high-risk prescribing in
primary care is common and its prevalence
varies substantially between practices (after
adjusting for case-mix), which indicates
scope for improvement.5–8 Given the current
UK policy focus on improving patient safety,
there is a need to develop and test interven-
tions to reduce high-risk prescribing.9 10
Strengths and limitations of this study
▪ The key strength of this study was the use of
quantitative and qualitative methods to give a
greater understanding of how changeable the
identified high-risk prescribing was, what the
barriers to changing prescribing were and how
general practitioners (GPs) valued this work.
▪ The findings of this pilot study enabled informed
choice of outcome measures and optimisation of
the intervention to be tested in the DQIP trial.
▪ The limitation of this study is that changeabilityof
potential outcome measures was tested by
measuring GPs intention to change prescribing
or conduct further investigation (‘action’), rather
than quantifying actual changes in prescribing
and their clinical implications (although this is
being evaluated in an ongoing clusterrandomised
controlled trial).
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In the UK, the virtually ubiquitous use of electronic
medical records (EMRs) in primary care offers opportun-
ities to support quality and safety improvement initiatives.
For example, the PINCER (Pharmacist-led Information
Technology Intervention for Medication Errors) trial has
demonstrated the effectiveness of an intervention, where
pharmacists identiﬁed patients with high-risk prescribing
using data extracted from EMRs, reviewed their records
and recommended changes.11 Similarly, the ‘Data-driven
quality improvement in primary care’ (DQIP) research
programme aims to identify patients with high-risk pre-
scribing from EMRs, but in contrast to PINCER, practices
are provided with continuous feedback using a web-based
informatics tool and ﬁnancial incentives to motivate prac-
tice staff to review patients identiﬁed.12
The Medical Research Council (MRC) framework
recommends that complex interventions be modelled
before evaluation in a randomised controlled trial in
order to optimise the intervention design and its evalu-
ation by deﬁning outcomes and ensuring feasibility.13 14
In terms of intervention design, the broad shape of the
DQIP intervention was deﬁned by the intention that
there should be evidence for the effectiveness of its com-
ponents, that it should be built on existing National
Health Service (NHS) information technology and be
implementable as an ‘enhanced service’ (a UK National
Health Service mechanism for commissioning general
practice care). The intention was therefore to combine
an educational intervention,15 16 audit and feedback,17
and a ﬁnancial incentive to review. As a result, a priority
was to pilot and optimise these elements in a small
number of practices. For evaluating the impact of the
intervention, a set of potential prescribing outcome mea-
sures had previously been validated using consensus
methods5 but an outstanding question was which of these
measures could plausibly be improved by this interven-
tion and therefore used as trial outcome measures.
The speciﬁc objectives of this study were to optimise the
DQIP intervention and trial evaluation by: (1) identifying
which potential outcome measures best identiﬁed patients
with high-risk prescribing that could potentially be
changed; (2) establishing which measures were most
valued by practices in terms of improving quality and
safety; (3) exploring how best to design and deliver the
educational, informatics and ﬁnancial components of the
DQIP intervention to maximise the practice engagement.
METHODS
Settings
We purposively sampled and recruited four general prac-
tices, two from each NHS Scotland Health Board where
the intervention was to be trialled, aiming to include
larger and smaller practices serving populations that
varied in socioeconomic deprivation.
Data collection
Data collection was between March 2010 and August 2011.
Quantitative data
In each practice, thematically related prescribing mea-
sures (‘prescribing topics’) that had been identiﬁed as
priorities for quality and safety improvement5 were
implemented in EMRs to identify patients with poten-
tially suboptimal prescribing for review. These prescrib-
ing topics were: (1) high-risk use of non-steroidal
anti-inﬂammatory drugs (NSAIDs) and antiplatelets in
patients with gastrointestinal, renal or cardiac risk
factors (‘NSAIDs and antiplatelets’); (2) underuse of
inhaled corticosteroids and high-risk use of β-blockers in
asthma (‘asthma control’) and (3) overuse and under-
use of antithrombotic drugs in atrial ﬁbrillation (AF)
(‘antithrombotics in AF’).
Practices received a feedback report for each topic,
which summarised the total numbers of patients identi-
ﬁed by each measure of high-risk prescribing, listed the
patients affected and provided supporting educational
material (rationale, current evidence and prescribing
guidance).18 Practices were asked to conduct a record
review of all identiﬁed patients with face-to-face review if
necessary, and to document all decision-making on a
structured template (tick boxes for a decision to ‘change
prescribing’, conduct ‘further investigation’ or ‘no
action’ and free text space to specify the rationale for
‘no action’). Our expectation was that clinicians would
judge some high-risk prescribing to be appropriate but
would identify other patients in whom the prescribing
should be stopped. An important aim of the pilot was to
estimate how appropriateness and stopping varied across
topics, to allow the trial to target prescribing that was
more likely to be inappropriate and changeable.
Qualitative data
An initial meeting to explain the study and describe the
topics was held in each practice. Practices then worked
on one topic at a time, with further meetings held 6–
8 weeks after practices had received and acted on the
feedback report. The meetings were facilitated by the
pharmacist (TD), and observed by AMG who took eth-
nographical ﬁeld notes of 18 h of meetings. The whole
practice was invited but the meetings were generally
attended by the GP(s) most involved and the practice
manager and lasted between 30 and 60 min. At these
meetings, practices were asked to describe the practice
processes to conduct the review work, to report on the
complexities of reviewing or changing prescribing and
to expand on reasons for ‘no action’.
The GPs most involved in the review work and practice
managers were invited for individual semistructured
interviews in order to explore their perceptions of the
value of each prescribing topic and the speciﬁc compo-
nents of the intervention (education, informatics and
ﬁnancial), their experiences of adopting and imple-
menting the intervention in routine practice and to
changing prescribing. Eleven interviews were conducted
with eight GPs (one GP was interviewed twice) and two
practice managers. These interviews were held in the
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practices, lasted approximately 1 h, were audiorecorded
and transcribed verbatim.
Data analysis
Quantitative analysis (research question (RQ) 1: performance
of prescribing measures)
The ability of each measure to identify potentially
changeable high-risk prescribing was measured as the
proportion of patients reviewed whose prescribing was
judged to require action (‘change prescribing’ or
‘further investigation’). Reasons why the measures failed
to identify potentially changeable high-risk prescribing
in patients were classiﬁed into three categories: ‘clinical’
(prescribing changes were deemed inappropriate or
unnecessary given the clinical circumstances), ‘tech-
nical’ (the measure misidentiﬁed patients when imple-
mented in live clinical data) and ‘other’.
Qualitative analysis (RQ2 perceived value of each prescribing
topic and RQ3 optimising intervention components)
Interview transcripts and ﬁeld notes were merged and
analysed by emerging themes to identify a coding frame.
Data were imported into Nvivo-8 and the coding frame
was systematically applied. Subsequent analysis was by
the framework technique.19 Thematic charting facili-
tated comparing the data by theme, practice and pre-
scribing topic. The data were explored for negative
cases.
RESULTS
Practice list-sizes ranged from 3200 to over 10 000, with
the percentage of patients living in the most deprived
quintile of postcodes ranging from 4% to 46%. All four
practices completed the ‘NSAID and antiplatelet’ and
‘asthma control’ topics, but only three completed the
‘antithrombotics in AF’ topic.
Ability of measures to identify patients with potentially
changeable high-risk prescribing
Table 1 shows that for the ‘NSAID and antiplatelet’
topic, practices recorded a need for action in 68% of
patients reviewed (change prescribing 35%; further
investigation 33%) compared with only 25% of patients
reviewed for the ‘asthma control’ topic (change prescrib-
ing 7%; further investigation 18%) and 18% of those
reviewed for ‘antithrombotics in AF’ (change prescribing
1%; further investigation 17%).
Table 2 shows the rationales for no action reported by
GPs on templates for each patient reviewed. Clinical
reasons were most commonly reported for the ‘NSAIDs
and antiplatelets’ topic (67%), but less so for the ‘antith-
rombotics in AF’ (36%) and much less for the ‘asthma
control’ (4%) topic. The reasons provided reﬂected that
high-risk prescribing was a trade-off between effective-
ness and safety. For ‘NSAIDs and antiplatelets’, the main
reported reason for not changing prescribing was that
NSAID use was only ‘short term’. For ‘antithrombotics
Table 1 Review decisions made by topic
Topic/individual measures implemented (number of reviews)
Number of times the following decisions were made
at point of review
Change
medication
Further
investigation No action
1 NSAIDS and antiplatelets (n=290) 101 (35%) 97 (33%) 92 (32%)
1.1 High-risk use in patients with GI risk factors (n=120)*,† 54 (45%) 21 (18%) 45 (38%)
1.2 High-risk use of NSAIDs in patients with renal risk factors
(n=161)‡
44 (27%) 72 (45%) 45 (28%)
1.3 High-risk use of NSAIDs in heart failure (n=9) 3 (33%) 4 (44%) 2 (22%)
2. Asthma (n=148) 10 (7%) 26 (18%) 112 (76%)
2.1 Underuse of inhaled corticosteroids (n=130)§ 7 (5%) 23 (18%) 100 (77%)
2.2 High-risk use of β-blockers (n=18)¶ 3 (17%) 3 (17%) 12 (67%)
3. Atrial fibrillation (n=201) 3 (1%) 34 (17%) 164 (82%)
3.1 Underuse/low intensity of thromboembolic prophylaxis (n=178) 1 (1%) 34 (19%) 143 (80%)
3.2 High-risk use of oral anticoagulants (n=23) 2 (9%) 0 (0%) 21 (91%)
The data reported on topics 1 (NSAID and antiplatelet) and 2 (asthma) measures are from all four practices and the topic 3 (atrial fibrillation)
data are from three of the pilot practices.
*NSAID prescription (in previous 12 weeks) without GI protection to people with at least one of the following risk factors: (i) history of peptic
ulcer, (ii) aged ≥75, (iii) aged ≥65 and on aspirin, (iv) aged ≥65 and on warfarin.
†Aspirin prescription (in previous 12 weeks) without GI protection to people with at least one of the following risk factors: (i) history of peptic
ulcer, (ii) aged ≥65 and on clopidogrel, (iii) aged ≥65 and on warfarin.
‡NSAID prescription to people with at least one of the following risk factors: (i) CKD stages 3–5, (ii) on ACEI/ARB, (iii) on diuretic, (iv) on
combination of ACEI/ARB and diuretic.
§No prescription of inhaled corticosteroid (in previous 12 weeks) in patient with asthma and at least one of the following risk factors: (i)
prescription for three or more SABA inhalers in previous 12 weeks, (ii) prescription of LABAs, leukotriene receptor antagonist, theophylline or
oral prednisolone in previous 12 weeks.
¶Prescription of any β-blocker if ‘active asthma’ (prescription of a SABA inhaler in previous 48 weeks) or prescription of a non-cardioselective
β-blocker if ‘previous asthma’ (no prescription of a SABA inhaler in the previous 48 weeks).
ACEI/ARB, ACE inhibitors/angiotensin receptor blocker; CKD, chronic kidney disease; GI, gastrointestinal; LABAs, long-acting β2-agonists;
NSAIDs, non-steroidal anti-inflammatory drugs; SABA, short acting β agonists.
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in AF’, clinical reasons reported were mainly ‘unﬁtness
for warfarin’ (examples reported in interview included
fragility and dementia, heavy alcohol use and previous
gastrointestinal bleeding), but also included ‘paroxysmal
AF’ (reﬂecting a misconception that stroke risk is lower
than for patients with chronic AF).20
‘Technical reasons’ accounted for one-third of ratio-
nales for no action for the ‘NSAID and antiplatelet’
topic, and for 47% ‘asthma control’ and 48% of the
‘antithrombotics in AF’ topics. For all three topics, tech-
nical reasons related to patients no longer being on
practice registers and to situations where identiﬁed high-
risk prescribing was no longer present at the point of
review (‘time window of assessment’). For example, for
the ‘antithrombotics in AF’ topic, all practices high-
lighted in interviews that anticoagulant prescribing inter-
vals often exceeded the 12-week timeframe used by the
measures, causing patients to be incorrectly identiﬁed as
lacking antithrombotic prophylaxis.
Inaccurate disease registers were reported as reasons
why ‘antithrombotics in AF’ and ‘asthma control’ mea-
sures misidentiﬁed prescribing as high risk. One practice
reported in interview that many patients on their asthma
disease register had chronic obstructive pulmonary
Table 2 Reasons stated by clinicians as to why ‘no action’ was required for patients identified with drug therapy risk(s) by
the DQIP measures
Topic (number of
reviews)
Number of reviews where stated reason for ‘no action’ was*
‘Technical’ (count, %) specific
reasons (count)
‘Clinical’ specific reasons
(count)
‘Other’ specific reasons
(count)
1. NSAIDS and
antiplatelets (n=92)
30 (33%) 62 (67%) 0
1.1 High-risk use in
patients with GI risk
factors (n=45)
10 (22%) 35 (78%) 0
Patient no longer on practice
register (5); time window of
assessment (3†); disease coding
error (2)
Short-term use (21); risk
adequately mitigated by low-dose
misoprostol (5); high-risk drug
‘well tolerated’ (9); no effective
alternative (5)
1.2 High-risk use of
NSAIDs in patients with
renal risk factors (n=45)
20 (44%) 20 (44%) 5 (11%)
Time window of assessment
(15†); patient no longer on
practice register (5)
Short-term use (19); no effective
alternative (1)
Unspecified (5‡)
1.3 High-risk use of
NSAIDs in heart failure
(n=2)
0 2 (100%) 0
Short-term use (2)
2. Asthma (n=112) 53 (47%) 5 (4%) 54 (48%)
2.1 Underuse of inhaled
corticosteroids (n=100)
46 (46%) 0 54 (54%)
Time window of assessment
(21†); proxies for moderate/
severe asthma failed (13§);
disease coding error (10); patient
no longer on practice register (2)
Needs review but does not
attend clinic (29); recently
reviewed for QOF (22);
patient choice (3)
2.2 High-risk use of
β-blockers (n=12)
7 (58%) 5 (42%) 0
Disease coding error (7) β-blocker ‘well tolerated’ (5)
3 AF (n=166) 80 (48%) 59 (36%) 27 (16%)
3.1 Underuse/low
intensity of
thromboembolic
prophylaxis (n=143)
78 (55%) 42 (29%) 23 (16%)
Disease coding error (31); time
window of assessment (29†);
patient no longer on practice
register (18)
Not ‘fit’ for warfarin (30);
paroxysmal AF (7); satisfactory
rate control (5)
Patient choice (16);
secondary care decision
(3); unspecified (4)
3.2 High-risk use of oral
anticoagulants (n=21)
2 (10%) 17 (81%) 2 (10%)
Disease coding error (2) CHADS2 score judged to
underestimate risk (17)
Secondary care decision
(2)
*The number of specific reasons may exceed the number of reviews when more than one reason was provided per review.
†Refers to situations where a drug that was identified by the searches as ‘high-risk’ was stopped or a drug identified as ‘beneficial’ was
prescribed between the search date and the review date.
‡The reasons provided referred to coexisting gastrointestinal risk factors.
§The proxies for moderate-to-severe asthma (>3 prescriptions of short-acting β agonists issued over the past 12 weeks; prescription of step 3
drugs) failed in these cases, because patients had mild asthma but were stock-piling inhalers (eg, getting them to have available in multiple
locations) or using step 3 drugs for indications other than asthma.
AF, atrial fibrillation; CHADS2, Additive stroke risk score (Cardiac failure (1), Hypertension (1), Age≥75 (1), Diabetes (1), Stroke (2)); DQIP,
data-driven quality improvement in primary care; GI, gastrointestinal; NSAIDs, non-steroidal anti-inflammatory drugs; QOF, quality and
outcomes framework.
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disease and therefore did not have a clear indication for
treatment with inhaled corticosteroids. The deprived
practices reported that high numbers of short-acting
β-agonist prescriptions did not necessarily identify
patients with uncontrolled asthma, because patients
stockpiled inhalers in multiple locations (eg, home,
school or work).
‘Other’ reasons were not commonly identiﬁed for
‘NSAIDs and antiplatelets’, but accounted for 16% of
‘antithrombotics in AF’ and for 48% of ‘asthma control’
reviews where no action was taken. For the latter, GPs
reported that patients had recently received an annual
quality and outcomes framework (QOF) review, usually
from a nurse, and they therefore assumed them to be
on optimised asthma treatment. GPs generally felt that
changes in prescribing for asthma usually required
face-to-face review but patients often did not respond to
invitations for review.
Perceived value of each prescribing topic as a target for
the DQIP intervention
GPs perceived the pilot intervention-raised awareness of
targeted high-risk prescribing, improved prescribing
practices and the recording of decision-making ratio-
nales, but they did not value each topic equally.
improving prescribing practice, improving our record
keeping, improving our knowledge base and if people
are on unsafe meds getting them off them and if there
are on them carefully considering why and it is not acci-
dental. (GP interview 1)
All GPs interviewed highly valued the process of
reviewing patients identiﬁed as receiving high-risk NSAID
or antiplatelet prescriptions.
The topic is, I would go so far as to say, essential. I don’t
even think you can say it’s urgent. It’s essential that prac-
tices are doing this. They could be killing patients totally
unnecessarily and it’s not as if it’s difﬁcult, because in a
lot of circumstances, the vast majority of them are non-
steroidals in elderly people. (GP interview 7)
The GPs interviewed perceived that NSAIDs are some-
times initiated with the intention the prescription was a
one-off or without full consideration of all risk factors.
I’ve always thought I’ve been quite cautious with NSAIDs
but then again possibly some of these patients were
mine. You know they have been started on NSAID
despite them being on ACE inhibitor and a diuretic and
you think oh god, that’s incredibly embarrassing. (GP
interview 6).
Where risk factors were missed or NSAIDs were pre-
scribed for longer than intended, GPs valued a prompt
to review. In the interviews, GPs reported changes to the
NSAID and antiplatelet prescribing were the least
complex decision-making of the topics, although all but
one GP (who felt NSAIDs had ‘no place’ in pain control
and patients should have no choice in whether to use
these drugs) highlighted that it is sometimes compli-
cated by patient’s choice.
You know it is a compromise—patients like them
[NSAIDs] because they’re effective, whatever anybody
says without a shadow of doubt people with osteoarthritis
ﬁnd them very effective drugs and often ﬁnd them far
more effective … for pain relief and symptom relief in
total … than any other medication we’ve got to give
them. (GP Interview 9)
Although the ‘antithrombotics in AF’ measures led to
limited changes in prescribing (3 changes from 201
reviews), two practices perceived the work to be worth-
while and for one it was their most valued prescribing
topic, because two patients and the practice were
relieved from the burden of unnecessary warfarin
therapy. Two practices felt that AF decision-making was
often in the hands of consultants, and all GPs reported
seeking advice from secondary care regarding the need
to initiate or continue warfarin in speciﬁc patients.
Although GPs reported the notes review work for AF was
the most complex, they found validating warfarin pre-
scribing a reassuring process.
the non-steroidal one was great. The atrial ﬁbrillation
one was great for a different matter, because [although]
you identiﬁed quite a lot of patients, at the end of the
day, when we looked through them, [we] only identiﬁed
one that we wanted to chase up. (GP interview 7)
The ‘asthma control’ topic was perceived as the least
important by all GPs, mainly because of overlap with
measures in QOF,21 and because they shared responsibil-
ity with practice nurses and were content to leave the
decision-making to them.
I think sometimes we could use the nurses to do some of
it…in the future when we do that we would ask our
nurse that does the asthma clinic to do that because that
would, you know she’s the one that’s doing the prescrib-
ing so that would’ve been better for her to take control
of that. (GP interview 9)
Optimising the intervention
Practice experiences identiﬁed some barriers which
facilitated optimising the intervention beyond sugges-
tions in the current literature on changing prescribing.
Facilitating engagement
GPs felt prescribing safety was important but that
improvement was always in the context of busy work-
loads. A ﬁnancial incentive to review was perceived as
important to facilitate engagement and to encourage
practices to participate in the trial. GPs were asked
about how any ﬁnancial incentive should be structured,
and different balances between up-front payments and
payment-per-review were discussed. Of the options
offered, all GPs and practice managers interviewed were
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in agreement that £350 (€411, US$538) upfront and £15
(€18, US$23) per review best struck the balance between
gaining attention and incentivising payment-per-review.
I think £350 up front and £15 per review. The reason for
this is that the work is very much about the review and if
you pay up-front too much, there is a danger the reviews
won’t get done as the incentive is small. In fact up-front
payment could be less, with more per review, provided
you have a mechanism for checking the review has been
done properly. (GP Interview 7)
This payment structure mirrors the existing ﬁnancial
incentives for quality in use in the UK general practice,
either in the QOF (an explicit pay for performance
system) or in enhanced service contracts for work not
covered by capitation.22
Maintaining engagement
Two practices struggled to embed the work within prac-
tice routines and expressed the concern that DQIP work
could be sidelined by competing work pressures. In add-
ition to the pay-per-review ﬁnancial incentive, it was
therefore decided that practices should receive regular
updates on their progress (or lack of progress) via DQIP
newsletters. It was anticipated that to maintain engage-
ment, unnecessary reviews had to be minimised. This
led to a change in how patients were identiﬁed so that
patients whose high-risk prescribing had been reviewed
and deemed appropriate would not be reﬂagged for
review for the same type of high-risk prescribing in the
next year.
Sustaining improved prescribing
All GPs interviewed valued the data but felt high-risk
NSAID prescribing required regular review. GPs per-
ceived this was the prescribing topic where prescribing
was likely to be restarted because of continuing patient’s
demand for analgesia and restarting by other doctors.
I think, it will always be very difﬁcult, you will always get
colleagues that will go back to prescribing it again and
what was interesting was when you were re-running the
searches, what was actually happening with that. Looking
at what we were doing, because sometimes Dr X would
say, ‘Crikey look at that! (Practice manager interview 2)
It was decided that the DQIP informatics tool would
need to reﬂag patients for review, where high-risk pre-
scribing was restarted after a decision to stop, and
provide run charts to allow practices to monitor high-
risk prescribing trends over time.
DISCUSSION
Summary of main findings
All topics examined in this study had previously been
identiﬁed as priorities for improvement in primary
care.5 GP review of the targeted prescribing revealed
that measures for each topic varied in their ability to
identify changeable high-risk prescribing and in their
perceived importance. The NSAID and antiplatelet mea-
sures performed the best in identifying potentially
changeable high-risk prescribing (68% of patients
required action vs 25% for the ‘asthma control’ and
18% of ‘antithrombotics in AF’) and were the most
valued. Although the ‘antithrombotics in AF’ topic gen-
erated considerable work for little change, it was highly
valued by two practices because it identiﬁed a small
number of patients who could stop warfarin, which mat-
tered given the treatment and monitoring burden this
drug imposes on patients and practices. The asthma
topic was the least valued due to overlaps with QOF
reviews and technical problems in accurately identifying
patients with poor asthma control from EMRs. These
ﬁndings demonstrate the importance of testing potential
outcome measures prior to trialling complex interven-
tions in order to ensure they are changeable by the
intervention to be evaluated.23–25 Although practices
mentioned improving prescribing safety was important,
a number of barriers to engagement, maintenance of
effort and sustaining improved prescribing were identi-
ﬁed which informed the intervention design24 26 and
ensured sensitivity to practices’ needs.25 These barriers
were addressed through ﬁnancial incentives per patient
reviewed, and the informatics component would provide
continuous measurement and feedback, supplemented
by monthly update newsletters.
Strengths and limitations
A strength of this study was the use of quantitative and
qualitative methods to give a broader understanding of
how changeable this high-risk prescribing was, what the
barriers to changing prescribing were and how GPs
valued this work, which enabled informed choice of
outcome measures and optimisation of the interven-
tion.24 26 27 In addition, the ﬁndings supported the
design of the trial process evaluation28 29 along with the
main trial design. The main limitation of this study is
that changeability of potential outcome measures was
tested by measuring GPs’ intention to change prescrib-
ing or conduct further investigation (‘action’), rather
than quantifying actual changes in prescribing and their
clinical implications. This did, however, allow the identi-
ﬁcation of plausible high-risk prescribing to use as an
outcome measure in the trial which will evaluate the
ability of the intervention to actually change prescribing.
It is worth noting that although the AF and asthma mea-
sures examined were found to be less suitable, this was
partly because of technical problems of operationalising
them in routine data, and optimising the technical prop-
erties of the measures (eg, by extending the time
window for warfarin prescriptions in order to reduce the
number of patients falsely identiﬁed as lacking antith-
rombotic prophylaxis) may improve their performance.
A second limitation of this study was the small number
of general practices and reviewing clinicians included,
and the four practices involved were of course all
6 Grant AM, Guthrie B, Dreischulte T. BMJ Open 2014;4:e004153. doi:10.1136/bmjopen-2013-004153
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volunteers, who may not be representative of all prac-
tices. This is inevitable in small pilot studies though, and
the main trial will evaluate the effectiveness in a wider
range of practices with a parallel process evaluation to
examine whether and how practices implement the
intervention.
Comparison with existing literature
Although there are many examples of studies developing
prescribing measures and establishing their face and
content validity,5 30–33 few have reported the extent to
which such measures can identify actual opportunities
for improvement.34 35 A Dutch study found that patients
identiﬁed by a measure-targeting underuse of inhaled
corticosteroids in asthma (using prescriptions of short-
acting β agonists as a proxy for uncontrolled asthma),
46% were candidates for inhaled steroids after a
face-to-face review by a clinician, compared with 25% at
best (assuming all ‘further investigations’ would conﬁrm
the need for inhaled steroids). The much lower propor-
tion found here suggests that estimates of changeability
are likely to be context speciﬁc (eg, depending on the
accuracy of data sources used) and may also depend on
the gold standard against which the performance of pre-
scribing measures is compared. When selecting outcome
measures for a trial, ﬁndings from previous studies con-
ducted in different healthcare settings may therefore be
of limited value.
Some of the prescribing measures evaluated here tar-
geted prescribing patterns similar to those used as
primary outcome measures in the PINCER trial.11 At
6 months of follow-up, the PINCER trial found a signiﬁ-
cant reduction in β-blocker prescribing in asthma and
NSAID prescribing (without use of gastroprotection in
patients with a history of peptic ulcer).36 However, part
of the improvement in high-risk NSAID prescribing was
lost by 12 months of follow-up, which is consistent with
concerns expressed by GPs in this study that NSAIDs
may be restarted due to patient demand or lack of com-
munication between GPs. The DQIP trial and parallel
process evaluations will establish to which extent the
strategies used in the DQIP intervention to avoid such
relapse (continuous feedback, paying per review and
regular letters highlighting progress) is successful.
Our ﬁnding that changing prescribing of antithrom-
botics in AF is difﬁcult to change is consistent with large
surveys conducted over the last 10–15 years, demonstrat-
ing little improvement in the uptake of anticoagulants in
patients with AF at high risk of stroke.37–39 Similar to our
study, a systematic review exploring barriers to prescrib-
ing anticoagulants for AF found that the main reasons
not to prescribe anticoagulants were advanced patient’s
age and perceived risk of bleeding events.40 A lower
uptake of anticoagulants in paroxysmal AF has also pre-
viously been reported, consistent with GPs reporting par-
oxysmal AF as a reason not to prescribe AF in this study,
although stroke risk is as high as in chronic AF.37 This
does not mean that such prescribing could not be
improved, but may indicate that more attention would
need to be paid to persuading GPs of the beneﬁts and
risks of antithrombotic use in people with AF, before
interventions like this one which prompt review. For the
‘Asthma control’ topic, some of the interviewed GPs
appeared to show complacency (eg, the assumption that
if patients have had a QOF asthma review they would be
on optimal treatment) and it is possible that where this
is the case, then more intensive educational or change
facilitating interventions may be required.
CONCLUSION
Although several studies using the RAND appropriate-
ness method have identiﬁed sets of ‘valid’ indicators,
their value and feasibility for change is not usually
assessed in terms of the extent to which they identify
patients with actual inappropriate prescribing.33 41 This
study shows their perceived value and feasibility may vary
by prescribing topic,34 42 and any research or NHS use of
prescribing indicators for improvement would therefore
beneﬁt from piloting and evaluation. Some prescribing
topics, such as NSAIDs, may be suitable for low-intensity
interventions based on repeated feedback using existing
electronic data, simple education and possibly small
ﬁnancial incentives but other prescribing topics, such as
‘asthma control’ and ‘antithrombotics in AF’ may require
prior work to clean electronic data and reﬁne measures,
or more intensive educational work to persuade practices
what is being measured is important, or more intensive
facilitation of change. Safer prescribing is an important
aim for policy and commissioners, but there may not be a
‘one size ﬁts all’ intervention to deliver it.
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